[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Singhal M, Raina V, Gupta R, Das P: T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report. Cases J; 2010;3:4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell-prolymphocytic leukemia detected in a patient of breast cancer at the time of recurrence: a case report.
  • INTRODUCTION: Therapy related second malignancy of the hematological system is small but real risk after adjuvant chemotherapy for breast cancer.
  • It includes acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); however T-cell prolymphocytic leukemia (T-PLL) has not been described earlier in relation to breast cancer and its therapy.
  • Histophotomicrograph of the excised breast lesion showed a 2.1 cm duct carcinoma, positive for ER and PR with 1 out of 25 lymph nodes positive for metastasis.
  • She received 6 cycles of chemotherapy with cyclophosphamide, epirubicin, and 5-fluorouracil.
  • Immunophenotying, established a diagnosis of post thymic T-cell prolymphocytic leukemia.
  • Contrast-enhanced computed tomography of the chest and abdomen was done which revealed an anterior mediastinal mass with destruction of sternum along with multiple small nodular shadows in bilateral lung fields suggestive of lung metastasis.
  • This confirmed a co-existent metastatic breast carcinoma.
  • She was started on chemotherapy for T-PLL along with hormonal therapy with aromatase inhibitor.
  • CONCLUSION: Our case describes the potential of breast chemotherapy to cause grave second hematological malignancies of the T-cell lymphoid lineage, not described earlier.
  • Such events highlight the importance to identify those patients of breast cancer in whom chemotherapy can safely be avoided.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2009 Feb 10;27(5):791-8 [19124806.001]
  • [Cites] BMC Cancer. 2007;7:152 [17683622.001]
  • [Cites] J Clin Oncol. 2007 Jan 20;25(3):292-300 [17159192.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4179-91 [15961765.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1721-6 [11535503.001]
  • [Cites] J Clin Oncol. 1994 Dec;12(12):2588-93 [7989933.001]
  • [Cites] N Engl J Med. 1992 Jun 25;326(26):1745-51 [1594016.001]
  • [Cites] J Clin Oncol. 1985 Dec;3(12):1640-58 [3906049.001]
  • [Cites] Clin Breast Cancer. 2003 Oct;4(4):273-9 [14651772.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2722-30 [8874333.001]
  • (PMID = 20076807.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2806858
  •  go-up   go-down


2. Lequaglie C, Della Morte A, Feudale E, Giudice G: [Solitary metachronous metastasis of the sternum from pancreatic adenocarcinoma]. Chir Ital; 2007 Nov-Dec;59(6):901-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary metachronous metastasis of the sternum from pancreatic adenocarcinoma].
  • [Transliterated title] Metastasi umica metacrona dello sterno da adenocarcinoma del pancreas.
  • Two years earlier, the patient reported on here, a 67-year-old man with a solitary osteolytic lesion of the sternal manubrium, had undergone a duodeno-cephalopancreatectomy for adenocarcinoma of the pancreas (G2, pY3, pN1) followed by adjuvant radio-chemotherapy.
  • PET/CT scans, in response to the onset of burning pain in the sternal region, revealed a hypermetabolic area only at the level of the manubrium, while MRI showed a bulging manubrium due to the presence of extensive solid pathological tissue towards the right articulations of the ribs.
  • The histological examination revealed secondary adenocarcinoma with 3 mediastinal metastatic lymph nodes.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Bone Neoplasms / surgery. Pancreatic Neoplasms. Sternum
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Lymph Node Excision. Magnetic Resonance Imaging. Male. Palliative Care. Pancreaticoduodenectomy. Positron-Emission Tomography. Prognosis. Radiotherapy, Adjuvant. Surgical Mesh. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18361001.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


3. Konishi K, Hasegawa N, Kaneko H, Iimura Y, Shoji Y, Kawabata M: [A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC]. Gan To Kagaku Ryoho; 2010 Jan;37(1):111-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of premenopausal stage IV breast cancer responding to neoadjuvant endocrine therapy after chemotherapy with FEC].
  • A 33-year-old woman was referred to our hospital with a complaint of left breast tumor.
  • After examinations, she was diagnosed as invasive ductal carcinoma with sternum metastasis (T2N0M1(OSS), Stage IV).
  • The tumor was hormone receptor- positive and HER2-negative.
  • Primary systemic chemotherapy with FEC was performed.
  • After chemotherapy, endocrine therapy with goserelin and tamoxifen was performed.
  • The efficacy of endocrine therapy was as good as that of chemotherapy.
  • After endocrine therapy for 13 months, breast conserving-surgery was performed.
  • After surgery, radiotherapy for left breast and sternum was performed.
  • She continues to undergo outpatient endocrine therapy with no detectable tumor.
  • It is suggested that neoadjuvant endocrine therapy may be useful with consideration for treatment effectiveness and the patient's quality of life.
  • [MeSH-major] Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Goserelin / administration & dosage. Tamoxifen / administration & dosage
  • [MeSH-minor] Adult. Cyclophosphamide / therapeutic use. Epirubicin / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Mastectomy. Neoadjuvant Therapy. Premenopause

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. GOSERELIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20087042.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen; 0F65R8P09N / Goserelin; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; FEC protocol
  •  go-up   go-down


Advertisement
4. Minamoto K, Ikeda T: [A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2627-30
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of advanced breast cancer with multiple bone metastases responding to docetaxel and high-dose toremifene as fourth-line chemo-endocrine therapy].
  • A 55-year old woman, who underwent left mastectomy (Bt+Ax), was revealed to have sternum metastasis by postoperative 99mTc bone scanning(T1bN1M1).
  • She received daily aromatase inhibitor (anastrozole), as a primary systemic endocrine therapy, and biweekly pamidronate for metastatic breast cancer.
  • However, she depended on folk medicine a year later, at which time the primary treatment was discontinued.
  • Another year later, the bone metastases developed with increased serum levels of tumor markers (CEA, CA19-9, and NCC-ST-439).
  • Then, she underwent three different regimens of systemic chemo-endocrine therapy over the following three years, including CAF+MPA as the first-line, paclitaxel (PTX) + anastrozole as the second-line, and S-1+anastrozole as the third-line regimen.
  • She recently completed 10 courses of the fourth-line regimen[tri-weekly docetaxel (DOC) and high-dose toremifene (TOR 120 mg/day)], which reduced levels of 99mTc accumulation in the multiple bone metastases and levels of the serum tumor markers to the normal range.
  • Combination treatment with DOC and high-dose TOR can be one of the worthwhile regimens as systemic chemo-endocrine therapy for patients with advanced breast cancer who develop bone metastases.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Taxoids / administration & dosage. Toremifene / administration & dosage

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009468.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Taxoids; 15H5577CQD / docetaxel; 7NFE54O27T / Toremifene
  •  go-up   go-down


5. Yasuda K, Kimura T, Seita M, Takahata T, Akazai Y: [A case of gastric cancer accompanied by disseminated carcinomatosis of bone marrow with DIC recovered by sequential therapy consisting of MTX and 5-FU]. Gan To Kagaku Ryoho; 2008 Nov;35(11):1941-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of gastric cancer accompanied by disseminated carcinomatosis of bone marrow with DIC recovered by sequential therapy consisting of MTX and 5-FU].
  • Endoscopy revealed gastric cancer with pyloric stenosis and MRI showed multiple metastasis of thoracic vertebral body.
  • Sternum bone marrow biopsy revealed poorly-differentiated adenocarcinoma.
  • Chemotherapy with sequential therapy consisting of MTX and 5-FU (MTX 150 mg/body, 5-FU 1,000 mg/body) was performed in addition to anti-DIC therapy.
  • Then, we changed the chemotherapy regimen to S-1/ paclitaxel (S-1 60 mg/body, PTX 60 mg/body).
  • After 2 courses, the primary tumor was remarkably reduced and CEA decreased to within normal limits.
  • After discharge, the patient has been undergoing chemotherapy on an outpatient basis.
  • [MeSH-major] Bone Marrow Neoplasms / drug therapy. Carcinoma / drug therapy. Disseminated Intravascular Coagulation / complications. Fluorouracil / therapeutic use. Methotrexate / analogs & derivatives. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Carcinoembryonic Antigen / blood. Humans. Male

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19011348.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 136181-93-6 / methotrexate-N,N'-bis(decylamide); U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


6. Feenstra J, Vermeer RJ, Stricker BH: Mesenteric venous thrombosis attributed to docetaxel. Am J Clin Oncol; 2000 Aug;23(4):353-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a 57-year-old woman with metastatic breast cancer unresponsive to several chemotherapeutic and hormonal regimens.
  • Because of progressive pulmonary metastases and a painful osteolytic metastasis in the sternum, treatment with docetaxel was initiated.
  • She developed mesenteric venous thrombosis within 1 week after the first dose of docetaxel.
  • Although docetaxel may be regarded as an important advancement in the chemotherapeutic treatment of several cancers, ongoing and future trials must assess its position in the standard chemotherapeutic treatment of cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Mesenteric Vascular Occlusion / chemically induced. Mesenteric Veins / drug effects. Paclitaxel / analogs & derivatives. Taxoids. Venous Thrombosis / chemically induced
  • [MeSH-minor] Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Middle Aged. Osteolysis / drug therapy. Sternum / pathology

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10955862.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Takahashi T, Akashi-Tanaka S, Fukutomi T, Watanabe T, Katsumata N, Miyakawa K, Hasegawa T, Tsuda H: Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin. Breast Cancer; 2001;8(3):234-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two special types of breast cancer presenting as progressive disease after neoadjuvant chemotherapy with docetaxel plus doxorubicin.
  • Seventy-eight patients with primary breast cancer over 3 cm in diameter in stages II A, II B, III A and III B according to the UICC classification received neoadjuvant chemotherapy from August 1, 1998 to June 30, 2000 at the Breast Division of the National Cancer Center Hospital.
  • Neoadjuvant chemotherapy consisted of doxorubicin (Adriamycin: ADM) 50 mg/m(2) and docetaxel (Taxotere: DOC) 60 mg/m(2) every three weeks.
  • Although neoadjuvant chemotherapy with this regimen achieved good responses in patients with breast cancer, 2 patients presented with progressive disease (PD) after treatment.
  • There were 4 cases of IBC and one case of SCC of the breast who received neoadjuvant chemotherapy in this series.
  • Our observations suggest that this regimen might not be effective for these types of breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Neoadjuvant Therapy. Paclitaxel / analogs & derivatives. Taxoids
  • [MeSH-minor] Adult. Disease Progression. Doxorubicin / administration & dosage. Female. Humans. Lymphatic Metastasis. Mammography. Middle Aged. Sternum

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11668246.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


8. Pavlakis G, Mountzios G, Terpos E, Leivaditou A, Papadopoulos G, Papasavas P: Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:299-303
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent ovarian cancer metastatic to the sternum, costae, and thoracic wall after prolonged treatment with platinum-based chemotherapy: a case report and review of the literature.
  • We present here a case of a 47-year-old woman with thoracic wall metastasis from serous-papillary ovarian carcinoma that occurred 3 years after the initial diagnosis, although the patient had received various regimens of intense platinum-based chemotherapy.
  • Special emphasis is given to the effects of alkylating agents, such as cisplatin and carboplatin, on the pattern of tumor spread.
  • We also discuss the possible mechanisms through which the biologic and metastatic behavior of this tumor is expressed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Neoplasms / drug therapy. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Cystadenocarcinoma, Papillary / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Epirubicin / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Recurrence, Local / therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Ribs. Sternum. Taxoids / administration & dosage. Thoracic Wall. Topotecan / administration & dosage. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515608.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; 5V9KLZ54CY / Vinblastine; 7M7YKX2N15 / Topotecan; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  • [Number-of-references] 10
  •  go-up   go-down


9. Yuasa H, Katsumine Y, Uehara S, Noda N, Osawa I: [Three cases of advanced breast cancer successfully treated with a weekly dose of paclitaxel]. Gan To Kagaku Ryoho; 2005 Apr;32(4):533-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Case 1: A 52-year-old female, diagnosed as having bilateral breast cancer with metastatis to right lung (S9) and sternum.
  • A TXL weekly regimen was started (80 mg/m2 with the administration of the drug for three weeks followed by one week rest as one course).
  • After twelve courses of treatment, bilateral breast masses significantly regressed with the disappearance of bilateral axillary and parasternal lymph node metastasis.
  • The tumor marker was normalized, too.
  • As a result of two courses of weekly TXL therapy, the tumor responded significantly and a modified mastectomy was conducted.
  • The TXL weekly regimen seems to be very effective in regressing breast tumors and can be given safely in the outpatient setting with an extremely high utility profile as neoadjuvant chemotherapy as well.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Nitriles / administration & dosage. Paclitaxel / administration & dosage. Triazoles / administration & dosage
  • [MeSH-minor] Antineoplastic Agents, Hormonal / administration & dosage. Bone Neoplasms / secondary. Drug Administration Schedule. Female. Humans. Lung Neoplasms / secondary. Mastectomy, Modified Radical. Middle Aged. Neoplasm Invasiveness. Skin Neoplasms / pathology. Sternum

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15853223.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Shaker MR, Yang G, Timme TL, Park SH, Kadmon D, Ren C, Ji X, Lee HM, Sehgal I, Anzano M, Sporn MB, Thompson TC: Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression. Clin Exp Metastasis; 2000;18(5):429-38
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression.
  • The effects of the synthetic retinoid N-(4-hydroxyphenyl) retinamide (4-HPR) on prostate cancer metastasis in vivo were evaluated in the mouse prostate reconstitution (MPR) model.
  • Previous studies have documented that loss of p53 function potentiates metastasis in this model system.
  • MPRs were grafted into homozygous (+/+) p53 male mice, fed a 4-HPR containing diet or a control diet and maintained until the status of tumor progression dictated sacrifice.
  • Under these experimental conditions, treatment with 4-HPR did not have a significant effect on primary tumor wet weight for either p53 +/- or p53 -/- MPRs.
  • Notably, in p53 +/- MPRs the incidence of metastasis to lumbar spine and sternum was 92% in the control animals compared to 54% in the 4-HPR treated animals (P = 0.035, chi2-test).
  • In p53 -/- MPRs there was a trend toward a reduction in the number of soft tissue metastases to lung and liver in the 4-HPR group relative to the control diet group and a statistically significant reduction in the incidence of metastasis to bone was demonstrated in that 50% of control animals versus 30% of 4-HPR treated p53 -/- animals harbored bone metastases (P = 0 < 0.05, chi2-test).
  • Cell lines were established from portions of the primary tumor and from selected metastatic deposits in each experimental group.
  • Clonal analysis, by retroviral integration pattern, indicated increased clonal diversity in both the primary tumors and metastasis-derived cell lines from 4-HPR treated animals relative to the control animals.
  • In vitro treatment with 4-HPR did not reveal discriminating differences between cell lines derived from primary tumors and bone metastases or control and treatment groups in regard to growth arrest or apoptotic responses.
  • Overall these studies indicate limited anti-tumor and anti-metastatic activity in this highly aggressive in vivo mouse model of prostate cancer, yet 4-HPR treatment significantly suppressed the development of bone metastases in p53 +/- and p53 -/- MPRs revealing a novel and potentially clinically useful activity of this retinoid.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bone Neoplasms / drug therapy. Fenretinide / pharmacology. Prostatic Neoplasms / secondary
  • [MeSH-minor] Animals. Cell Division / drug effects. Diet. Disease Models, Animal. Male. Mice. Survival Rate. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 1989 Mar 24;56(6):917-30 [2538247.001]
  • [Cites] Cancer Res. 1991 Jul 1;51(13):3610-1 [1829024.001]
  • [Cites] Biotechniques. 1994 Sep;17(3):460, 462-3 [7818898.001]
  • [Cites] Clin Exp Metastasis. 1994 Jan;12(1):63-72 [8287622.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5408-14 [7585610.001]
  • [Cites] Prostate. 2000 Jun 1;43(4):248-54 [10861743.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4614-7 [8062253.001]
  • [Cites] Oncogene. 1995 Mar 2;10(5):869-79 [7534899.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1285-90 [9515817.001]
  • [Cites] Cancer Res. 1976 Jul;36(7 PT 2):2626-30 [819130.001]
  • [Cites] Fed Proc. 1976 May 1;35(6):1332-8 [770206.001]
  • [Cites] J Steroid Biochem Mol Biol. 1995 May;52(5):403-13 [7538321.001]
  • [Cites] Cancer Res. 1993 Oct 1;53(19):4461-5 [8402613.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Urology. 1994 Jun;43(6):828-33 [7515206.001]
  • [Cites] J Urol. 1995 Nov;154(5):1818-24 [7563355.001]
  • [Cites] Cancer Res. 1994 Jun 15;54(12):3273-7 [7515768.001]
  • [Cites] Oncol Res. 1999;11(1):1-8 [10451026.001]
  • [Cites] Cancer Lett. 1991 Aug;59(2):159-63 [1832081.001]
  • (PMID = 11467776.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 50588; United States / NCI NIH HHS / CA / CA 68814; United States / PHS HHS / / P50-58204
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 187EJ7QEXL / Fenretinide
  •  go-up   go-down


11. Oura S, Sakurai T, Yoshimura G, Tamaki T, Umemura T, Kokawa Y, Naito Y: [Pain relief with alendronate therapy in a breast cancer patient with bone metastasis]. Gan To Kagaku Ryoho; 2000 Apr;27(4):633-7
Hazardous Substances Data Bank. Alendronic acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pain relief with alendronate therapy in a breast cancer patient with bone metastasis].
  • A 66-year-old woman developed a bone metastasis from breast cancer to the sternum in September, 1997.
  • She received alendronate therapy, consisting of biweekly intravenous administrations of 10 mg-alendronate 6 times and monthly 20 mg-alendronate infusions 15 times.
  • The first alendronate administration markedly alleviated her bone pain.
  • However, an elevation of tumor marker levels in serum without any pain increase forced us to treat her with medroxyprogesterone acetate and doxifluridine in addition to the alendronate therapy.
  • With these therapies, she has shown an objective response (PR) of the bone metastasis for 8 months.
  • In conclusion, alendronate therapy was effective against bone pain due to metastasis of breast cancer.
  • [MeSH-major] Alendronate / therapeutic use. Bone Neoplasms / physiopathology. Bone Neoplasms / secondary. Breast Neoplasms / pathology. Pain / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Hormonal / administration & dosage. Female. Floxuridine / administration & dosage. Humans. Medroxyprogesterone Acetate / administration & dosage. Sternum

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Pain.
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10791010.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 039LU44I5M / Floxuridine; C2QI4IOI2G / Medroxyprogesterone Acetate; V1JK16Y2JP / doxifluridine; X1J18R4W8P / Alendronate
  •  go-up   go-down


12. Shimoyama T, Yoshiya K, Yamato Y, Koike T, Honma K: Long-term survival after removal of a malignant peripheral nerve sheath tumor originating in the anterior mediastinum. Gen Thorac Cardiovasc Surg; 2009 Jun;57(6):310-4
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival after removal of a malignant peripheral nerve sheath tumor originating in the anterior mediastinum.
  • Malignant peripheral nerve sheath tumors (MPNSTs; malignant schwannomas) rarely occur in the anterior mediastinum, and their prognosis is poor.
  • A 75-year-old man was referred to our hospital for examination of an anterior mediastinal tumor.
  • A computed tomography-guided percutaneous needle biopsy revealed only fibrosis.
  • The tumor was completely excised via a median sternotomy with partial resection of the pericardium and right upper lobe of the lung.
  • Thereafter, the tumor was diagnosed as a storiform-pleomorphic type of malignant fibrous histiocytoma.
  • At 1 year after the surgery, a distant metastasis was found in the interlobular space between the right middle and lower lobes.
  • The tumor was completely excised via a right posterolateral thoracotomy.
  • Reexamination of the primary and secondary tumors revealed an MPNST.
  • No recurrence was found up to 5 years after the second surgery without adjuvant chemotherapy or radiation therapy.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / surgery. Mediastinal Neoplasms / surgery. Nerve Sheath Neoplasms / surgery. Pericardiectomy. Pneumonectomy. Sternum / surgery
  • [MeSH-minor] Aged. Biopsy, Needle. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Male. Thoracotomy. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1998 Jun 1;82(11):2191-203 [9610699.001]
  • [Cites] Chest. 1995 Aug;108(2):574-5 [7634904.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Oct;128(4):615-7 [15457164.001]
  • [Cites] J Chin Med Assoc. 2006 Jan;69(1):37-41 [16447925.001]
  • [Cites] Ann Thorac Surg. 2003 May;75(5):1645-8 [12735601.001]
  • [Cites] World J Surg Oncol. 2005 Oct 06;3:65 [16207383.001]
  • [Cites] Monaldi Arch Chest Dis. 2006 Dec;65(4):222-4 [17393668.001]
  • [Cites] Cancer. 1971 May;27(5):1190-201 [5581511.001]
  • [Cites] Respiration. 2000;67(3):346-7 [10867610.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • (PMID = 19533278.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


13. Kunisue H, Kurebayashi J, Sonoo H, Udagawa K, Yamamoto Y, Yamamoto S, Tanaka K, Shimozuma K: [A case of advanced breast cancer associated with humoral hypercalcemia that responded to medroxyprogesterone acetate and docetaxel]. Gan To Kagaku Ryoho; 2000 Jul;27(7):1043-6
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest CT revealed a parasternal lymph nodal metastasis invading into the sternum, an axillary lymph nodal metastasis, and a lung metastasis.
  • After controlling the hypercalcemia with alendronate, sodium hydrate she received chemoendocrine therapy with medroxyprogesterone acetate (MPA) (800 mg/day) and docetaxel (60 mg/body once every three weeks).
  • A complete response was obtained in the primary and metastatic lesions after 3 cycles of docetaxel.
  • This case suggests the efficacy of the combined therapy with MPA and docetaxel on advanced breast cancers.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Hypercalcemia / complications. Lymph Nodes / pathology. Taxoids
  • [MeSH-minor] Administration, Oral. Aged. Axilla. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Medroxyprogesterone Acetate / administration & dosage. Neoplasm Invasiveness. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10925692.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; C2QI4IOI2G / Medroxyprogesterone Acetate; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


14. Fujimoto R, Higashi T, Nakamoto Y, Hara T, Lyshchik A, Ishizu K, Kawashima H, Kawase S, Fujita T, Saga T, Togashi K: Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET. Ann Nucl Med; 2006 Jul;20(6):399-408
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of bone metastases detection in cancer patients: comparison between bone scintigraphy and whole-body FDG-PET.
  • 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) has become widely available and an important oncological technique.
  • To evaluate the influence of PET on detection of bone metastasis, we compared the diagnostic accuracy of PET and conventional bone scintigraphy (BS) in a variety of cancer patients.
  • A whole-body PET (from face to upper thigh) and a standard whole body BS were performed and these images were interpreted by two experienced nuclear medicine physicians with and without patient information using monitor diagnosis.
  • Each image interpretation was performed according to 8 separate areas (skull, vertebra, upper limbs, sternum and clavicles, scapula, ribs, pelvis, and lower limbs) using a 5-point-scale (0: definitely negative, 1: probably negative, 2: equivocal, 3: probably positive, 4: definitely positive for bone metastasis).
  • RESULTS: Twenty-one of 95 patients (22.1%) with 43 of 760 areas (5.7%) of bone metastases were finally confirmed.
  • In untreated patients, 12 of 14 bone metastasis positive patients were detected by PET, while 9 of 14 were detected by BS.
  • Three cases showed true positive in PET and false negative in BS due to osteolytic type bone metastases.
  • In untreated cases, PET with and without clinical information showed better sensitivity than BS in patient-based diagnosis.
  • For the purpose of treatment effect evaluation, PET showed better results because of its ability in the evaluation of rapid response of tumor cells to chemotherapy.
  • There was only one solitary lesion located outside of FOV of PET scan in the femur, but with clinical information that was no problem for PET diagnosis.
  • CONCLUSION: Diagnostic accuracy of bone metastasis was comparable in PET and BS in the present study.
  • In a usual clinical condition, limited FOV (from face to upper thigh) of PET scan may not be a major drawback in the detection of bone metastases because of the relatively low risk of solitary bone metastasis in skull bone and lower limbs.
  • [MeSH-major] Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods. Technetium Tc 99m Medronate / analogs & derivatives. Whole Body Imaging / methods

  • Genetic Alliance. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16922468.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 72945-61-0 / technetium Tc 99m hydroxymethylene diphosphonate; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


15. Alifano M, Parri SN, Arab WA, Bonfanti B, Lacava N, Porrello C, Boaron M: Limited upper sternotomy in general thoracic surgery. Surg Today; 2008;38(4):300-4
MedlinePlus Health Information. consumer health - Chest Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thyroid surgery constituted the second main indication for upper sternal split (n = 32) for benign retrosternal goiter in 18 patients, for mediastinal nodal metastasis of thyroid cancer in 11, and for malignant retrosternal goiter in 3.
  • The remaining indications were as follows: to assess residual disease following chemotherapy for Hodgkin's disease in 7 patients and for non-Hodgkin lymphoma in 1; for tracheal surgery in 7; and for excision of nodal mediastinal metastasis of non-thyroid cancer in 2.
  • There was no surgical mortality but complications developed in eight patients.
  • CONCLUSION: The upper sternal split provides a satisfactory access to perform a surgical procedure in the superior mediastinum in most diseases.
  • The procedure is safe and involves minimal surgical trauma.
  • [MeSH-major] Sternum / surgery. Thoracic Diseases / surgery. Thoracic Surgical Procedures / methods
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Myasthenia Gravis / surgery. Retrospective Studies. Thymoma / surgery. Thymus Neoplasms / surgery. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):204-8 [12118759.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Apr;21(4):664-70 [11932165.001]
  • [Cites] Laryngoscope. 1998 Nov;108(11 Pt 1):1611-7 [9818814.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Sep;22(3):352-6 [12204722.001]
  • [Cites] Ann Thorac Surg. 1988 Mar;45(3):242-7 [3348695.001]
  • [Cites] Eur J Cardiothorac Surg. 1989;3(6):504-9; discussion 510-1 [2635936.001]
  • [Cites] Ann Thorac Surg. 2004 Mar;77(3):1107-8 [14992948.001]
  • [Cites] Anesth Analg. 2003 Nov;97(5):1257-9 [14570633.001]
  • [Cites] Ann Thorac Surg. 2001 May;71(5):1721-3 [11383846.001]
  • [Cites] Acta Chir Belg. 2000 Nov-Dec;100(6):259-63 [11236179.001]
  • [Cites] Chest Surg Clin N Am. 1996 Feb;6(1):85-93 [8646506.001]
  • [Cites] Chest. 1995 Jul;108(1):78-82 [7606997.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1999 Jan;11(1):59-64 [9930714.001]
  • [Cites] Ann Thorac Surg. 1997 Feb;63(2):563-6 [9033349.001]
  • [Cites] Ann Thorac Surg. 1996 Jul;62(1):242-5 [8678650.001]
  • [Cites] Ann Thorac Surg. 1998 Jun;65(6):1520-2 [9647051.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2209-13; discussion 2213-4 [10617004.001]
  • [Cites] J Card Surg. 2000 Jan-Feb;15(1):15-20 [11204383.001]
  • (PMID = 18368317.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


16. Milardovic R, Castellon I, Mills C, Altinyay ME, Raphael B, Abdel-Dayem HM: Scintigraphic visualization of an epigastric sentinel node in recurrent breast cancer after lumpectomy and postoperative radiation therapy. Clin Nucl Med; 2006 Apr;31(4):207-8
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scintigraphic visualization of an epigastric sentinel node in recurrent breast cancer after lumpectomy and postoperative radiation therapy.
  • Failure to visualize a sentinel lymph node in recurrent breast cancer after treatment by surgery, chemotherapy, and high-dose postoperative radiation therapy is almost the case in every patient.
  • The reason for failure to visualize the sentinel node is the fibrosis that follows high-dose radiotherapy and blocks the lymphatics preventing spread of the tumor cells to the lymph nodes.
  • Alternative pathways for the drainage of lymph from the breast are developed in these patients.
  • In this report, we are presenting another alternative pathway of lymphatics to the region of the epigastrium below the lower end of the sternum.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Lymphatic Metastasis / radionuclide imaging
  • [MeSH-minor] Female. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Sentinel Lymph Node Biopsy. Sternum

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550014.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Chapelier A, Fadel E, Macchiarini P, Lenot B, Le Roy Ladurie F, Cerrina J, Dartevelle P: Factors affecting long-term survival after en-bloc resection of lung cancer invading the chest wall. Eur J Cardiothorac Surg; 2000 Nov;18(5):513-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Several reports emphasize the importance of en-bloc resection as the optimal surgical treatment of lung cancer with chest wall invasion.
  • Chest wall resection also extended to the sternum in one patient, the transverse process in one, the costotransverse foramen and hemivertebrae in two.
  • Sixty-three patients received postoperative radiotherapy and 12 received chemotherapy.
  • The role of induction chemotherapy for tumors with poor prognosis should be investigated.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy. Female. Follow-Up Studies. Hospital Mortality. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11053809.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


18. Zhu DD, Yang ZQ: [Surgical treatment of transclavicular and transsternal tumor]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Nov;41(11):848-50
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of transclavicular and transsternal tumor].
  • OBJECTIVE: To investigate surgical treatment approach of transclavicular and transsternal tumor.
  • METHODS: Twelve cases of neck-root and mediastinum thoracis tumor subjected to cervicothoracic-combined surgical treatment were retrospectively analyzed and summarized.
  • RESULTS: Seven cases of benign tumor survived 1-8 years after surgery.
  • The other 5 patients were malignant tumor.
  • Among 4 cases of metastatic squamous cell carcinoma without definite origin at neck-root site who underwent operation and routine radiotherapy, one case died of orthotopic relapse and armpit metastasis at the 16th months postoperatively; one case was lost of follow-up after surgery; another two cases showed no relapse after follow-up of 50 months and 27 months, respectively.
  • In addition, one case of thyroid papillary carcinoma located at neck-root and mediastinum remained alive for 40 months after operation combined with radiotherapy and chemotherapy.
  • CONCLUSIONS: The evaluation of twelve cases of transclavicular and transsternal tumor with adoption of cervicothoracic-combined surgical approach improves and develops traditional knowledge of surgical therapy of neck-root tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Clavicle / pathology. Female. Humans. Male. Mediastinal Neoplasms / pathology. Middle Aged. Retrospective Studies. Sternum / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283540.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


19. Rai Y, Ando M, Sagara Y, Takahama T, Matsuyama Y, Ooi Y, Sagara Y: [Neoadjuvant endocrine therapy with anastrozole significantly downstaged an elderly breast cancer woman with locally-advanced breast cancer which became operable]. Gan To Kagaku Ryoho; 2005 Sep;32(9):1301-5
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant endocrine therapy with anastrozole significantly downstaged an elderly breast cancer woman with locally-advanced breast cancer which became operable].
  • A 73-year-old postmenopausal woman had a 13 cm-sized huge tumor in her left breast with an extensive purple skin color change.
  • The tumor decreased in size gradually and became operable after 7.5 months of the anastrozole monotherapy.
  • The resected specimen showed a 3.5 cm sized tumor with significant fibrosis and scanty viable tumor cells.
  • We concluded that neoadjuvant therapy with anastrozole is a good choice for receptor-positive postmenopausal breast cancer, especially for elderly or poor risk women.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Mastectomy. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Neoadjuvant Therapy. Postmenopause. Preoperative Care. Sternum

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16184928.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


20. Sawai K, Nakajima H, Mizuta N, Sakaguchi K, Hachimine Y: [Key issues in sentinel node biopsy for breast cancer]. Gan To Kagaku Ryoho; 2004 Aug;31(8):1271-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thus, sentinel node surgery has been accepted as a safe and accurate method of screening the axillary nodes for metastasis in women with small breast cancer.
  • SNB for patients with ductal carcinoma in situ (DCIS) may be performed according to the decision of doctors or patients in each case, because the indication of SNB for DCIS is controversial.
  • Since preoperative chemotherapy could increase the rate of false-negative sentinel nodes because of the induced lymphatic changes, SNB is thought to be safer before than after preoperative chemotherapy.
  • Current evidence does not allow internal mammary SNB to be recommended as a standard procedure, but as patients with internal mammary node involvement may benefit from adjuvant systemic treatment, internal mammary SNB should be further studied in this context.
  • Preoperative diagnosis of an axillary metastasis using fine-needle aspiration cytology (FNAC) under ultrasonographical imaging or core needle biopsy under MR imaging can cost-effectively decrease the indications of SNB.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Staging / classification. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Carcinoma, Intraductal, Noninfiltrating / pathology. Female. Humans. Lymph Node Excision. Lymphatic Metastasis / pathology. Sternum

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15332557.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 18
  •  go-up   go-down


21. Wegener B, Müller PE, Jansson V, Krödel A, Heinert G, Dürr HR: Cervical spine metastasis of multiple myeloma: a case report with 16 years of follow-up. Spine (Phila Pa 1976); 2004 Sep 1;29(17):E368-72
MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical spine metastasis of multiple myeloma: a case report with 16 years of follow-up.
  • It slowly causes bone destruction due to bone marrow infiltration.
  • RESULTS: Initial surgical treatment was aimed at palliation.
  • The patient died 16 years after the first procedure due to progression of the disease.
  • Surgical interventions must take into account the relatively long period of survival in multiple myeloma patients compared to patients with other secondary bone tumors.
  • [MeSH-major] Cervical Vertebrae. Multiple Myeloma / secondary. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Fatal Outcome. Follow-Up Studies. Humans. Ilium / radiography. Magnetic Resonance Imaging. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Osteolysis / etiology. Osteolysis / radiography. Palliative Care. Radiotherapy, Adjuvant. Reoperation. Sacrum / radiography. Spinal Stenosis / etiology. Spinal Stenosis / surgery. Sternum / radiography. Thoracic Vertebrae / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534399.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Bobek V, Plachy J, Pinterova D, Kolostova K, Boubelik M, Jiang P, Yang M, Hoffman RM: Development of a green fluorescent protein metastatic-cancer chick-embryo drug-screen model. Clin Exp Metastasis; 2004;21(4):347-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a green fluorescent protein metastatic-cancer chick-embryo drug-screen model.
  • The chick-embryo model has been an important tool to study tumor growth, metastasis, and angiogenesis.
  • However, an imageable model with a genetic fluorescent tag in the growing and spreading cancer cells that is stable over time has not been developed.
  • We report here the development of such an imageable fluorescent chick-embryo metastatic cancer model with the use of green fluorescent protein (GFP).
  • GFP-Lewis lung carcinoma metastases were visualized by fluorescence, after seven days additional incubation, in the brain, heart, and sternum of the developing chick embryo, with the most frequent site being the brain.
  • The combination of streptokinase and gemcitabine was evaluated in this GFP metastatic model.
  • The data in this report suggest that this new stably fluorescent imageable metastatic-cancer chick-embryo model will enable rapid screening of new antimetastatic agents.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Disease Models, Animal. Drug Screening Assays, Antitumor / methods. Green Fluorescent Proteins / metabolism. Neoplasm Metastasis / prevention & control
  • [MeSH-minor] Animals. Carcinoma, Lewis Lung / drug therapy. Chick Embryo. Mice. Mice, Inbred C57BL. Streptokinase / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 1999 May;35(5):808-14 [10505043.001]
  • [Cites] Proc Soc Exp Biol Med. 1954 Oct;87(1):223-7 [13224733.001]
  • [Cites] Blood Coagul Fibrinolysis. 1995 Apr;6(2):105-12 [7605874.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):546-56 [12217792.001]
  • [Cites] Med Hypotheses. 1980 Feb;6(2):145-92 [6993886.001]
  • [Cites] Biochemistry. 1997 Feb 4;36(5):1123-8 [9033403.001]
  • [Cites] Clin Exp Metastasis. 1994 Nov;12(6):357-67 [7923988.001]
  • [Cites] Gene. 1985;34(2-3):357-62 [2989113.001]
  • [Cites] Anat Rec. 1964 Jul;149:425-41 [14208987.001]
  • [Cites] Lancet. 1974 Aug 17;2(7877):382-4 [4137344.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1505-9 [7878009.001]
  • [Cites] Blood. 1988 May;71(5):1475-9 [3359049.001]
  • [Cites] J Biol Chem. 1995 Jan 27;270(4):1785-90 [7530248.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3):362-74 [10864223.001]
  • [Cites] J Exp Med. 1978 Jun 1;147(6):1584-95 [567240.001]
  • [Cites] Cancer Res. 1949 Jan;9(1):61-4 [18110414.001]
  • [Cites] Gan No Rinsho. 1972 Apr;18(4):285-9 [4337719.001]
  • [Cites] Blood. 2000 Nov 15;96(10):3302-9 [11071621.001]
  • [Cites] Science. 1964 Jan 10;143(3602):105-10 [14075717.001]
  • [Cites] Blood. 1985 Nov;66(5):1028-34 [2413926.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):57-60 [11206839.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:101-11 [1309029.001]
  • [Cites] Thromb Haemost. 1997 May;77(5):894-900 [9184399.001]
  • [Cites] Semin Thromb Hemost. 1998;24(2):93-109 [9579631.001]
  • [Cites] Ann Med Exp Biol Fenn. 1956;34(Suppl 9):1-81 [13411709.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):5360-6 [9030612.001]
  • [Cites] J Gen Physiol. 1945 Mar 20;28(4):363-83 [19873427.001]
  • [Cites] J Natl Cancer Inst. 1992 May 20;84(10):797-803 [1573668.001]
  • (PMID = 15554391.001).
  • [ISSN] 0262-0898
  • [Journal-full-title] Clinical & experimental metastasis
  • [ISO-abbreviation] Clin. Exp. Metastasis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1 R43 CA 099258; United States / NCI NIH HHS / CA / 1 R43 CA 103563
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 147336-22-9 / Green Fluorescent Proteins; B76N6SBZ8R / gemcitabine; EC 3.4.- / Streptokinase
  •  go-up   go-down






Advertisement